Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma

Dummer, R; Long, GV; Robert, C; Tawbi, HA; Flaherty, KT; Ascierto, PA; Nathan, PD; Rutkowski, P; Leonov, O; Dutriaux, C; Mandala, M; Lorigan, P; Ferrucci, PF; Grob, JJ; Meyer, N; Gogas, H; Stroyakovskiy, D; Arance, A; Brase, JC; Green, S; Haas, T; Masood, A; Gasal, E; Ribas, A; Schadendorf, D

Dummer, R (通讯作者)，Univ Zurich Hosp, Dept Dermatol, Gloriastr 31, CH-8091 Zurich, Switzerland.

JOURNAL OF CLINICAL ONCOLOGY, 2022; 40 (13): 1428

Abstract

PURPOSE Preclinical data suggest the combination of an anti-programmed death receptor 1 antibody plus dabrafenib and trametinib to have superior antit......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索